5-Lipoxygenase inhibitors: a review of recent developments and patents

Bibliography

• Peters-Golden M, Henderson WR, Jr. Leukotrienes. N Engl J Med 2007;357:1841-54
   PubMed Web of Science ®Google Scholar
• Radmark O. Arachidonate 5-lipoxygenase. J Lipid Mediat Cell 1995;12:171-84
   PubMedGoogle Scholar
• Samuelsson B, Dahlen SE, Lindgren JA, Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-6
   PubMed Web of Science ®Google Scholar
• Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006;58:375-88
   PubMed Web of Science ®Google Scholar
• Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008;8:349-61
   PubMed Web of Science ®Google Scholar
• Bannenberg GL. Resolvins: Current understanding and future potential in the control of inflammation. Curr Opin Drug Discov Devel 2009;12:644-58
   PubMedGoogle Scholar
• Brink C, Dahlen SE, Drazen J, International Union of Pharmacology XXXVII. Nomenclature for leukotriene and lipoxin receptors. Pharmacol Rev 2003;55:195-227
   PubMed Web of Science ®Google Scholar
• Maekawa A, Kanaoka Y, Xing W, Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors. Proc Natl Acad Sci US A 2008;105:16695-700
   PubMed Web of Science ®Google Scholar
• Grant GE, Rokach J, Powell WS. 5-Oxo-ETE and the OXE receptor. Prostaglandins Other Lipid Mediat 2009;89:98-104
   PubMed Web of Science ®Google Scholar
• Wan M, Sabirsh A, Wetterholm A, Leukotriene B4 triggers release of the cathelicidin LL-37 from human neutrophils: novel lipid-peptide interactions in innate immune responses. Faseb J 2007;21:2897-905
   PubMed Web of Science ®Google Scholar
• Claesson HE, Dahlen SE. Asthma and leukotrienes: antileukotrienes as novel anti-asthmatic drugs. J Intern Med 1999;245:205-27
   PubMed Web of Science ®Google Scholar
• Peters-Golden M. Expanding roles for leukotrienes in airway inflammation. Curr Allergy Asthma Rep 2008;8:367-73
   PubMed Web of Science ®Google Scholar
• Back M, Sakata K, Qiu H, Endothelium-dependent vascular responses induced by leukotriene B4. Prostaglandins Other Lipid Mediat 2007;83:209-12
   PubMed Web of Science ®Google Scholar
• Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001;14:3-19
   PubMed Web of Science ®Google Scholar
• Vannella KM, McMillan TR, Charbeneau RP, Cysteinyl leukotrienes are autocrine and paracrine regulators of fibrocyte function. J Immunol 2007;179:7883-90
   PubMed Web of Science ®Google Scholar
• Austen KF. Additional functions for the cysteinyl leukotrienes recognized through studies of inflammatory processes in null strains. Prostaglandins Other Lipid Mediat 2007;83:182-7
   PubMed Web of Science ®Google Scholar
• Chen XS, Sheller JR, Johnson EN, Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-82
   PubMed Web of Science ®Google Scholar
• Chen M, Lam BK, Kanaoka Y, Neutrophil-derived leukotriene B4 is required for inflammatory arthritis. J Exp Med 2006;203:837-42
   PubMed Web of Science ®Google Scholar
• Radmark O. 5-lipoxygenase-derived leukotrienes: mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol 2003;23:1140-2
   PubMed Web of Science ®Google Scholar
• Spanbroek R, Grabner R, Lotzer K, Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci US A 2003;100:1238-43
   PubMed Web of Science ®Google Scholar
• Cipollone F, Mezzetti A, Fazia ML, Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol 2005;25:1665-70
   PubMed Web of Science ®Google Scholar
• Back M, Bu DX, Branstrom R, Leukotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci US A 2005;102:17501-6
   PubMed Web of Science ®Google Scholar
• Helgadottir A, Manolescu A, Thorleifsson G, The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004;8:8
   Google Scholar
• Back M, Sultan A, Ovchinnikova O, 5-Lipoxygenase-activating protein: a potential link between innate and adaptive immunity in atherosclerosis and adipose tissue inflammation. Circ Res 2007;100:946-9
   PubMed Web of Science ®Google Scholar
• Riccioni G, Capra V, D'Orazio N, Leukotriene modifiers in the treatment of cardiovascular diseases. J Leukoc Biol 2008;84:1374-8
   PubMed Web of Science ®Google Scholar
• Werz O, Steinhilber D. Therapeutic options for 5-lipoxygenase inhibitors. Pharmacol Ther 2006;112:701-18
   PubMed Web of Science ®Google Scholar
• Radmark O, Werz O, Steinhilber D, 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci 2007;32:332-41
   PubMed Web of Science ®Google Scholar
• Mahshid Y, Lisy MR, Wang X, High expression of 5-lipoxygenase in normal and malignant mantle zone B lymphocytes. BMC Immunol 2009;10:2
   PubMed Web of Science ®Google Scholar
• Spanbroek R, Stark HJ, Janssen-Timmen U, 5-Lipoxygenase expression in Langerhans cells of normal human epidermis. Proc Natl Acad Sci US A 1998;95:663-8
   PubMed Web of Science ®Google Scholar
• Berg C, Hammarstrom S, Herbertsson H, Platelet-induced growth of human fibroblasts is associated with an increased expression of 5-lipoxygenase. Thromb Haemost 2006;96:652-9
   PubMed Web of Science ®Google Scholar
• Uz T, Dwivedi Y, Savani PD, Glucocorticoids stimulate inflammatory 5-lipoxygenase gene expression and protein translocation in the brain. J Neurochem 1999;73:693-9
   PubMedGoogle Scholar
• Ikonomovic MD, Abrahamson EE, Uz T, Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 2008;56:1065-73
   PubMed Web of Science ®Google Scholar
• Werz O. 5-lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy 2002;1:23-44
   PubMedGoogle Scholar
• Pergola C, Dodt G, Rossi A, ERK-mediated regulation of leukotriene biosynthesis by androgens: a molecular basis for gender differences in inflammation and asthma. Proc Natl Acad Sci US A 2008;105:19881-6
   PubMed Web of Science ®Google Scholar
• Hamano N, Terada N, Maesako K, Effect of sex hormones on eosinophilic inflammation in nasal mucosa. Allergy Asthma Proc 1998;19:263-9
   PubMed Web of Science ®Google Scholar
• Osman M. Therapeutic implications of sex differences in asthma and atopy. Arch Dis Child 2003;88:587-90
   PubMed Web of Science ®Google Scholar
• Haribabu B, Verghese MW, Steeber DA, Targeted disruption of the leukotriene B(4) receptor in mice reveals its role in inflammation and platelet-activating factor-induced anaphylaxis. J Exp Med 2000;192:433-8
   PubMed Web of Science ®Google Scholar
• Poeckel D, Zemski Berry KA, Murphy RC, Dual 12/15- and 5-lipoxygenase deficiency in macrophages alters arachidonic acid metabolism and attenuates peritonitis and atherosclerosis in ApoE knock-out mice. J Biol Chem 2009;284:21077-89
   PubMed Web of Science ®Google Scholar
• Hemak J, Gale D, Brock TG. Structural characterization of the catalytic domain of the human 5-lipoxygenase enzyme. J Mol Model (Online) 2002;8:102-12
   PubMed Web of Science ®Google Scholar
• Werz O, Tretiakova I, Michel A, Caspase-mediated degradation of human 5-lipoxygenase in B lymphocytic cells. Proc Natl Acad Sci US A 2005;102:13164-9
   PubMed Web of Science ®Google Scholar
• Rouzer CA, Samuelsson B. The importance of hydroperoxide activation for the detection and assay of mammalian 5-lipoxygenase. FEBS Lett 1986;204:293-96
   PubMed Web of Science ®Google Scholar
• Weitzel F, Wendel A. Selenoenzymes regulate the activity of leukocyte 5-lipoxygenase via the peroxide tone. J Biol Chem 1993;268:6288-92
   PubMed Web of Science ®Google Scholar
• Ochi K, Yoshimoto T, Yamamoto S, Arachidonate 5-lipoxygenase of guinea pig peritoneal polymorphonuclear leukocytes. Activation by adenosine 5′-triphosphate. J Biol Chem 1983;258:5754-8
   PubMed Web of Science ®Google Scholar
• Werz O, Klemm J, Samuelsson B, 5-lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci US A 2000;97:5261-6
   PubMed Web of Science ®Google Scholar
• Werz O, Burkert E, Fischer L, Extracellular signal-regulated kinases phosphorylate 5-lipoxygenase and stimulate 5-lipoxygenase product formation in leukocytes. Faseb J 2002;16:1441-3
   PubMed Web of Science ®Google Scholar
• Werz O, Szellas D, Steinhilber D, Radmark O. Arachidonic acid promotes phosphorylation of 5-lipoxygenase at Ser-271 by MAPKAP kinase-2. J Biol Chem 2002;277:14793-800
   Google Scholar
• Werz O, Klemm J, Rådmark O, Samuelsson B. p38 MAP kinase mediates stress-induced leukotriene synthesis in a human B-lymphocyte cell line. J Leuk Biol 2003;70:830-8
   Google Scholar
• Werz O, Burkert E, Samuelsson B, Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 2002;99:1044-52
   PubMed Web of Science ®Google Scholar
• Werz O, Klemm J, Samuelsson B, Phorbol ester up-regulates capacities for nuclear translocation and phosphorylation of 5-lipoxygenase in Mono Mac 6 cells and human polymorphonuclear leukocytes. Blood 2001;97:2487-95
   PubMed Web of Science ®Google Scholar
• Flamand N, Luo M, Peters-Golden M, Phosphorylation of serine 271 on 5-lipoxygenase and its role in nuclear export. J Biol Chem 2009;284:306-13
   PubMed Web of Science ®Google Scholar
• Lepley RA, Muskardin DT, Fitzpatrick FA. Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. J Biol Chem 1996;271:6179-84
   PubMed Web of Science ®Google Scholar
• Luo M, Jones SM, Phare SM, Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523. J Biol Chem 2004;279:41512-20
   PubMed Web of Science ®Google Scholar
• Provost P, Doucet J, Hammarberg T, 5-Lipoxygenase interacts with coactosin-like protein. J Biol Chem 2001;276:16520-7
   PubMed Web of Science ®Google Scholar
• Rakonjac M, Fischer L, Provost P, Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotriene A4 production. Proc Natl Acad Sci US A 2006;103:13150-5
   PubMed Web of Science ®Google Scholar
• Esser J, Rakonjac M, Hofmann B, Coactosin-like protein functions as a stabilizing chaperone for 5-lipoxygenase: role of tryptophan 102. Biochem J 2009
   Google Scholar
• Evans JF, Ferguson AD, Mosley RT, What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sci 2008;29:72-8
   PubMed Web of Science ®Google Scholar
• Uozumi N, Kume K, Nagase T, Role of cytosolic phospholipase A(2) in allergic response and parturition. Nature 1997;390:618-22
   PubMed Web of Science ®Google Scholar
• Tai N, Kuwabara K, Kobayashi M, Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. Inflamm Res 2010;59:53-62
   Google Scholar
• Nagase T, Uozumi N, Aoki-Nagase T, A potent inhibitor of cytosolic phospholipase A2, arachidonyl trifluoromethyl ketone, attenuates LPS-induced lung injury in mice. Am J Physiol Lung Cell Mol Physiol 2003;284:L720-6
   PubMed Web of Science ®Google Scholar
• Bellido-Reyes YA, Akamatsu H, Kojima K, Cytosolic phospholipase A2 inhibition attenuates ischemia-reperfusion injury in an isolated rat lung model. Transplantation 2006;81:1700-7
   PubMed Web of Science ®Google Scholar
• Ferguson AD, McKeever BM, Xu S, Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein. Science 2007;317:510-2
   PubMed Web of Science ®Google Scholar
• Lorrain DS, Bain G, Correa LD, Pharmacological Characterization of AM103, a Novel Selective Five-lipoxygenase-Activating Protein (FLAP) Inhibitor Reduces Acute and Chronic Inflammation. J Pharmacol Exp Ther 2009;331:1042-50
   Google Scholar
• Ford-Hutchinson AW, Gresser M, Young RN. 5-Lipoxygenase. Annu. Rev. Biochem 1994;63:383-417
   Google Scholar
• McMillan RM, Walker ERH. Designing therapeutically effective 5-lipoxygenase inhibitors. Trends Pharmacol Sci 1992;13:323-30
   PubMed Web of Science ®Google Scholar
• Werz O, Steinhilber D. Pharmacological intervention with 5-lipoxygenase: new insights and novel compounds. Exp Opin Ther Patents 2005;15:505-19
   Web of Science ®Google Scholar
• Brooks CDW, Stewart AO, Basha A, R-(+)-N-[3-[5-(4-Fluorophenyl)methyl]-2-thienyl]-1-methyl-2-propynyl]-N-hydroxyurea (ABT-761), a second generation 5-lipoxygenase inhibitor. J Med Chem 1995;38:4768-75
   PubMed Web of Science ®Google Scholar
• Lehnigk B, Rabe KF, Dent G, Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J 1998;11:617-23
   PubMed Web of Science ®Google Scholar
• Back M. Inhibitors of the 5-lipoxygenase pathway in atherosclerosis. Curr Pharm. Des 2009;15:3116-32
   PubMed Web of Science ®Google Scholar
• Werz O, Steinhilber D. Development of 5-lipoxygenase inhibitors-lessons from cellular enzyme regulation. Biochem Pharmacol 2005;70:327-33
   PubMed Web of Science ®Google Scholar
• Safayhi H, Mack T, Sabieraj J, Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 1992;261:1143-46
   PubMed Web of Science ®Google Scholar
• Siemoneit U, Pergola C, Jazzar B, On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance. Eur J Pharmacol 2009;606:246-54
   PubMed Web of Science ®Google Scholar
• Sengupta K, Alluri KV, Satish AR, A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res. Ther 2008;10:R85
   Google Scholar
• Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem. The dual inhibition concept. Pharmacol Res 2001;43:429-36
   PubMed Web of Science ®Google Scholar
• Sampson AP. FLAP inhibitors for the treatment of inflammatory diseases. Curr Opin Investig Drugs 2009;10:1163-72
   PubMedGoogle Scholar
• Tahitian Noni International. Lipoxygenase and cyclooxygenase inhibition. WO/2008/067410 (2008)
   Google Scholar
• Doiron J, Boudreau LH, Picot N, Synthesis and 5-lipoxygenase inhibitory activity of new cinnamoyl and caffeoyl clusters. Bioorg Med Chem Lett 2009;19:1118-21
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Abdellatif KR, Dong Y, Synthesis of celecoxib analogs that possess a N-hydroxypyrid-2(1H)one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2008;18:6138-41
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Chen H, Abdellatif KR, Synthesis and biological evaluation of 1-(benzenesulfonamido)-2-[5-(N-hydroxypyridin-2(1H)-one)]acetylene regioisomers: a novel class of 5-lipoxygenase inhibitors. Bioorg Med Chem Lett 2008;18:4195-8
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Abdellatif KR, Dong Y, Synthesis of celecoxib analogues possessing a N-difluoromethyl-1,2-dihydropyrid-2-one 5-lipoxygenase pharmacophore: biological evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. J Med Chem 2009;52:1525-9
   PubMed Web of Science ®Google Scholar
• Chowdhury MA, Abdellatif KR, Dong Y, Synthesis of 1-(methanesulfonyl- and aminosulfonylphenyl)acetylenes that possess a 2-(N-difluoromethyl-1,2-dihydropyridin-2-one) pharmacophore: evaluation as dual inhibitors of cyclooxygenases and 5-lipoxygenase with anti-inflammatory activity. Bioorg Med Chem Lett 2009;19:584-8
   PubMed Web of Science ®Google Scholar
• Shirumalla RK, Naruganahalli KS, Dastidar SG, RBx 7,796: A novel inhibitor of 5-lipoxygenase. Inflamm Res 2006;55:517-27
   PubMed Web of Science ®Google Scholar
• Shirumalla RK, Sharma P, Dastidar SG, Pharmacodynamic and pharmacokinetic characterisation of RBx 7796: a novel 5-lipoxygenase inhibitor. Inflamm Res 2008;57:135-43
   PubMed Web of Science ®Google Scholar
• Grimm EL, Brideau C, Chauret N, Substituted coumarins as potent 5-lipoxygenase inhibitors. Bioorg Med Chem Lett 2006;16:2528-31
   PubMed Web of Science ®Google Scholar
• Merck Frosst Canada Ltd Substituted quinolines as inhibitors of leukotriene biosynthesis. WO 2007/038865 (2007)
   Google Scholar
• Merck Frosst Canada Ltd Novel substituted 1,2,3-t&pgr;azolylmethyl-benzothiophene or -indole and their use as leukot&pgr;ene biosynthesis inhibitors. WO 2007/016784 (2007)
   Google Scholar
• Merck & Co. Chromenone derivatives and their use for leukotriene biosynthesis inhibition. WO 2009/042098 (2009)
   Google Scholar
• Mano T, Stevens RW, Ando K, Optimization of imidazole 5-lipoxygenase inhibitors and selection and synthesis of a development candidate. Chem Pharm Bull (Tokyo) 2005;53:965-73
   PubMed Web of Science ®Google Scholar
• Fischer L, Steinhilber D, Werz O. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol 2004;142:861-8
   PubMed Web of Science ®Google Scholar
• Cortes-Burgos LA, Zweifel BS, Settle SL, CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain. Eur J Pharmacol 2009;617:59-67
   PubMed Web of Science ®Google Scholar
• Pfizer Products INC. Pyrazole analogs. WO/2008/065493 (2008)
   Google Scholar
• Pfizer Products INC. Pyrazole derivatives as 5-LO inhibitors. WO/2009/069044 (2009)
   Google Scholar
• Ranbaxy. Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors. EP 1 834 953 A1 (2007)
   Google Scholar
• Goethe-University JW, Main Fa. 5-Arylalkylidene-2-arylalkyl-thiazol-4-one derivatives as inhibitors of 5-lipoxygenase and uses thereof. WO/2009/027077 (2009)
   Google Scholar
• Analyticon Discovery GmbH. Tetrahydronaphthol-derivatives and use thereof. WO/2007/115836 (2007)
   Google Scholar
• Toagosei Co Ltd 5-Lipoxygenase inhibitor. JP 2005229100 (2005)
   Google Scholar
• EWHA Foundation UIC. New benzoxazole derivative, process for the preparation thereof and pharmaceutical composition comprising the same. WO/2008/035956 (2008)
   Google Scholar
• Logigal Therapeutics INC. Compositions including leukotriene antagonists and nsaids and methods of using the same. WO/2009/012425 (2009)
   Google Scholar
• Laufer S, Tries S, Augustin J, Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclo-oxygenase and 5-lipoxygenase. Arzneimittelforschung 1994;44:629-36
   PubMed Web of Science ®Google Scholar
• Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002;51:135-43
   PubMed Web of Science ®Google Scholar
• Fischer L, Hornig M, Pergola C, The molecular mechanism of the inhibition by licofelone of the biosynthesis of 5-lipoxygenase products. Br J Pharmacol 2007;152:471-80
   PubMed Web of Science ®Google Scholar
• Koeberle A, Siemoneit U, Buhring U, Licofelone suppresses prostaglandin E2 formation by interference with the inducible microsomal prostaglandin E2 synthase-1. J Pharmacol Exp Ther 2008;326:975-82
   PubMed Web of Science ®Google Scholar
• Koeberle A, Siemoneit U, Northoff H, MK-886, an inhibitor of the 5-lipoxygenase-activating protein, inhibits cyclooxygenase-1 activity and suppresses platelet aggregation. Eur J Pharmacol 2009;608:84-90
   PubMed Web of Science ®Google Scholar
• Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep 2008;10:43-8
   PubMedGoogle Scholar
• Merckle GmbH. Macrolide conjugates of pyrrolizine and indolizine compounds as inhibitors of 5-lipooxygenase and cyclooxygenase. WO/2007/012464 (2007)
   Google Scholar
• Sud'ina GF, Pushkareva MA, Shephard P, Cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) selectivity of COX inhibitors. Prostaglandins Leukot Essent Fatty Acids 2008;78:99-108
   PubMed Web of Science ®Google Scholar
• Maier TJ, Tausch L, Hoernig M, Celecoxib inhibits 5-lipoxygenase. Biochem Pharmacol 2008;76:862-72
   PubMed Web of Science ®Google Scholar
• Scholz M, Ulbrich HK, Soehnlein O, Diaryl-dithiolanes and -isothiazoles: COX-1/COX-2 and 5-LOX-inhibitory, *OH scavenging and anti-adhesive activities. Bioorg Med Chem 2009;17:558-68
   PubMed Web of Science ®Google Scholar
• Chen QH, Rao PN, Knaus EE. Synthesis and biological evaluation of a novel class of rofecoxib analogues as dual inhibitors of cyclooxygenases (COXs) and lipoxygenases (LOXs). Bioorg Med Chem 2006;14:7898-909
   PubMedGoogle Scholar
• Rao PN, Chen QH, Knaus EE. Synthesis and structure-activity relationship studies of 1,3-diarylprop-2-yn-1-ones: dual inhibitors of cyclooxygenases and lipoxygenases. J Med Chem 2006;49:1668-83
   PubMed Web of Science ®Google Scholar
• Li L, Ji H, Sheng L, The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor. Eur J Pharmacol 2009;607:244-50
   PubMed Web of Science ®Google Scholar
• Zheng M, Zhang Z, Zhu W, Essential structural profile of a dual functional inhibitor against cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX): molecular docking and 3D-QSAR analyses on DHDMBF analogues. Bioorg Med Chem 2006;14:3428-37
   PubMed Web of Science ®Google Scholar
• Araico A, Terencio MC, Alcaraz MJ, Phenylsulphonyl urenyl chalcone derivatives as dual inhibitors of cyclo-oxygenase-2 and 5-lipoxygenase. Life Sci 2006;78:2911-8
   PubMed Web of Science ®Google Scholar
• Araico A, Terencio MC, Alcaraz MJ, Evaluation of the anti-inflammatory and analgesic activity of Me-UCH9, a dual cyclooxygenase-2/5-lipoxygenase inhibitor. Life Sci 2007;80:2108-17
   PubMed Web of Science ®Google Scholar
• Xu GL, Liu F, Zhao Y, Biological evaluation of 2-(4-amino-phenyl)-3-(3,5-dihydroxylphenyl) propenoic acid. Basic Clin Pharmacol Toxicol 2009;105:350-6
   PubMed Web of Science ®Google Scholar
• Xu GL, Liu F, Ao GZ, Anti-inflammatory effects and gastrointestinal safety of NNU-hdpa, a novel dual COX/5-LOX inhibitor. Eur J Pharmacol 2009;611:100-6
   PubMed Web of Science ®Google Scholar
• Koeberle A, Zettl H, Greiner C, Pirinixic acid derivatives as novel dual inhibitors of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. J Med Chem 2008;51:8068-76
   PubMed Web of Science ®Google Scholar
• Koeberle A, Werz O. Inhibitors of the Microsomal Prostaglandin E(2) Synthase-1 as Alternative to Non Steroidal Anti-inflammatory Drugs (NSAIDs) - A Critical Review. Curr Med Chem 2009;16:7924-32
   Google Scholar
• Werz O, Greiner C, Koeberle A, Novel and potent inhibitors of 5-lipoxygenase product synthesis based on the structure of pirinixic acid. J Med Chem 2008;51:5449-53
   PubMed Web of Science ®Google Scholar
• Landwehr J, George S, Karg EM, Design and synthesis of novel 2-amino-5-hydroxyindole derivatives that inhibit human 5-lipoxygenase. J Med Chem 2006;49:4327-32
   PubMedGoogle Scholar
• Karg EM, Luderer S, Pergola C, Structural optimization and biological evaluation of 2-substituted 5-hydroxyindole-3-carboxylates as potent inhibitors of human 5-lipoxygenase. J Med Chem 2009;52:3474-83
   PubMed Web of Science ®Google Scholar
• Koeberle A, Haberl EM, Rossi A, Discovery of benzo[g]indol-3-carboxylates as potent inhibitors of microsomal prostaglandin E(2) synthase-1. Bioorg Med Chem 2009;17:7924-32
   PubMed Web of Science ®Google Scholar
• Liedtke AJ, Keck PR, Lehmann F, Arylpyrrolizines as inhibitors of microsomal prostaglandin E2 synthase-1 (mPGES-1) or as dual inhibitors of mPGES-1 and 5-lipoxygenase (5-LOX). J Med Chem 2009;52:4968-72
   PubMed Web of Science ®Google Scholar
• Koeberle A, Northoff H, Werz O. Curcumin blocks prostaglandin E2 biosynthesis through direct inhibition of the microsomal prostaglandin E2 synthase-1. Mol Cancer Ther 2009;8:2348-55
   PubMed Web of Science ®Google Scholar
• Koeberle A, Bauer J, Verhoff M, Green tea epigallocatechin-3-gallate inhibits microsomal prostaglandin E(2) synthase-1. Biochem Biophys Res. Commun 2009;388:350-4
   Google Scholar
• Albert D, Zundorf I, Dingermann T, Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem Pharmacol 2002;64:1767-75
   PubMed Web of Science ®Google Scholar
• Feisst C, Pergola C, Rakonjac M, Hyperforin is a novel type of 5-lipoxygenase inhibitor with high efficacy in vivo. Cell Mol Life Sci 2009;66:2759-71
   PubMed Web of Science ®Google Scholar